Atezolizumab With EBRT for Bladder Preservation in MIBC

By Ovidio Fernandez Calvo, MD - Last Updated: June 13, 2024

Ovidio Fernandez Calvo, MD, of Complejo Hospitalario Universitario de Ourense, offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial.

Dr. Calvo and colleagues sought to determine the efficacy and safety of atezolizumab with concurrent radiotherapy in patients with muscle-invasive bladder cancer.

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Disitamab Vedotin Plus Toripalimab Shows Promise as Neoadjuvant Therapy in HER2-Expressing MIBC

Emily MenendezMuscle Invasive Urothelial Carcinoma | February 20, 2025

Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.

RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC

Pooja Ghatalia, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025

Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.

NIAGARA: Impact of pCR on Long-Term Outcomes

Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 14, 2025

Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.

CheckMate 274: Additional Efficacy Outcomes in Patients With MIBC

Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025

Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.

Atezolizumab With EBRT for Bladder Preservation in MIBC

Related Posts